217 related articles for article (PubMed ID: 15998666)
1. Efalizumab for the treatment of moderate to severe plaque psoriasis.
Jordan JK
Ann Pharmacother; 2005 Sep; 39(9):1476-82. PubMed ID: 15998666
[TBL] [Abstract][Full Text] [Related]
2. Efalizumab in the treatment of psoriasis: mode of action, clinical indications, efficacy, and safety.
Schön MP
Clin Dermatol; 2008; 26(5):509-14. PubMed ID: 18755369
[TBL] [Abstract][Full Text] [Related]
3. CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.
Dubertret L; Sterry W; Bos JD; Chimenti S; Shumack S; Larsen CG; Shear NH; Papp KA;
Br J Dermatol; 2006 Jul; 155(1):170-81. PubMed ID: 16792770
[TBL] [Abstract][Full Text] [Related]
4. Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab.
Cather JC; Cather JC; Menter A
Expert Opin Biol Ther; 2003 Apr; 3(2):361-70. PubMed ID: 12662148
[TBL] [Abstract][Full Text] [Related]
5. Efalizumab: a review of its use in the management of chronic moderate-to-severe plaque psoriasis.
Frampton JE; Plosker GL
Am J Clin Dermatol; 2009; 10(1):51-72. PubMed ID: 19170413
[TBL] [Abstract][Full Text] [Related]
6. [Efalizumab].
Descamps V
Ann Dermatol Venereol; 2006; 133(8-9 Pt 1):666-78. PubMed ID: 17053736
[TBL] [Abstract][Full Text] [Related]
7. An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis.
Joshi A; Bauer R; Kuebler P; White M; Leddy C; Compton P; Garovoy M; Kwon P; Walicke P; Dedrick R
J Clin Pharmacol; 2006 Jan; 46(1):10-20. PubMed ID: 16397279
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneously administered efalizumab (anti-CD11a) improves signs and symptoms of moderate to severe plaque psoriasis.
Gottlieb AB; Miller B; Lowe N; Shapiro W; Hudson C; Bright R; Ling M; Magee A; McCall CO; Rist T; Dummer W; Walicke P; Bauer RJ; White M; Garovoy M
J Cutan Med Surg; 2003; 7(3):198-207. PubMed ID: 12717587
[TBL] [Abstract][Full Text] [Related]
9. Efalizumab: new drug. Plaque psoriasis: too many unknowns.
Prescrire Int; 2006 Feb; 15(81):8-11. PubMed ID: 16548097
[TBL] [Abstract][Full Text] [Related]
10. Efalizumab.
Wellington K; Perry CM
Am J Clin Dermatol; 2005; 6(2):113-8; discussion 119-20. PubMed ID: 15799683
[TBL] [Abstract][Full Text] [Related]
11. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.
Menter A; Kosinski M; Bresnahan BW; Papp KA; Ware JE
J Drugs Dermatol; 2004; 3(1):27-38. PubMed ID: 14964744
[TBL] [Abstract][Full Text] [Related]
12. The Greek experience with efalizumab in psoriasis from a University Dermatologic Hospital.
Antoniou C; Stefanaki I; Stratigos A; Avgerinou G; Stavropoulos P; Potouridou I; Polidorou D; Moustou AE; Kosmadaki M; Katsambas AD
Br J Dermatol; 2007 Apr; 156 Suppl 2():12-6. PubMed ID: 17371318
[TBL] [Abstract][Full Text] [Related]
13. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.
Lebwohl M; Tyring SK; Hamilton TK; Toth D; Glazer S; Tawfik NH; Walicke P; Dummer W; Wang X; Garovoy MR; Pariser D;
N Engl J Med; 2003 Nov; 349(21):2004-13. PubMed ID: 14627785
[TBL] [Abstract][Full Text] [Related]
14. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
Gordon KB; Papp KA; Hamilton TK; Walicke PA; Dummer W; Li N; Bresnahan BW; Menter A;
JAMA; 2003 Dec; 290(23):3073-80. PubMed ID: 14679270
[TBL] [Abstract][Full Text] [Related]
15. Efalizumab in the treatment of psoriasis.
Gupta AK; Cherman AM
J Cutan Med Surg; 2006; 10(2):57-68. PubMed ID: 17241576
[TBL] [Abstract][Full Text] [Related]
16. Efalizumab: an overview.
Leonardi CL
J Am Acad Dermatol; 2003 Aug; 49(2 Suppl):S98-104. PubMed ID: 12894132
[TBL] [Abstract][Full Text] [Related]
17. Efalizumab, a reversible T-cell modulator for psoriasis.
Shear NH; Langley RG; Ho V
J Cutan Med Surg; 2006; 9 Suppl 1():4-9. PubMed ID: 16633862
[TBL] [Abstract][Full Text] [Related]
18. Long-term treatment of plaque psoriasis with efalizumab: an Italian experience.
Costanzo A; Peris K; Talamonti M; Di Cesare A; Fargnoli MC; Botti E; Chimenti S
Br J Dermatol; 2007 Apr; 156 Suppl 2():17-23. PubMed ID: 17371319
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
[TBL] [Abstract][Full Text] [Related]
20. Efalizumab.
Chacko M; Weinberg JM
Dermatol Ther; 2007; 20(4):265-9. PubMed ID: 17970891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
